Cost-effectiveness of primary HPV genotyping and dual-stain or cytology reflex testing versus cytology-based screening for cervical cancer in Chile
PLOS One · 04.03.2026 · 21 (3) · e0332010
DOI: 10.1371/journal.pone.0332010 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 04.03.2026. Verfasst von Nicolas Armijo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Epsilon Research, Santiago, Chile. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Early Detection of Cancer, Papillomavirus Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Roche.
Abstract (Originalsprache)
Testing for high-risk human papillomavirus with genotyping for types 16 and 18 (HPV16/18) and triage by p16/Ki-67 dual-stain immunocytochemistry improves diagnostic performance in cervical cancer screening. We estimated the cost-effectiveness of HPV DNA–based primary screening strategies that detect high-risk genotypes every 5 years with either reflex cytology (hrHPV–Pap-5) or reflex dual stain (CINtec® PLUS, Roche; hereafter hrHPV–CINtec-5) versus cytology every 3 years (SoC (PAP-3)) among women aged 25–64 years, from the Chilean public healthcare perspective. A state-transition microsimulation reflected the natural history of cervical cancer in screening-eligible Chilean women, using local epidemiology and literature-informed inputs. Direct medical costs were obtained from official Chilean sources and converted to USD (1 USD = 938 CLP). Deterministic and probabilistic sensitivity analyses were conducted; a 30–64 years initiation scenario was also evaluated. Both high-risk HPV DNA-based strategies were more effective and cost-saving than SoC (PAP-3). In the 25–64 base case, hrHPV–CINtec-5 yielded the greatest health gain (13,003 incremental Quality-Adjusted Life Year, hereafter QALYs) with $16.65 saved per woman, while hrHPV–Pap-5 saved $32.57 with 12,844 QALYs. Probabilistic sensitivity analysis confirmed dominance (most simulations in the southeast quadrant) and cost-effectiveness acceptability >90% across willingness-to-pay ranges. Deterministic analysis highlighted progression risk from HPV16/18 and the discount rate as key drivers. Transitioning from PAP-3 to high-risk HPV DNA-based primary screening in Chile is projected to improve health outcomes while reducing costs. Among HPV DNA-based strategies detecting high-risk genotypes evaluated, triage with hrHPV–CINtec-5 provided the largest health gain while remaining cost-saving; hrHPV–Pap-5 maximized cost savings. These findings support modernizing the national screening program.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Epsilon Research, Santiago, Chile.
- School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, China.
ORCID-Profile: Nicolas Armijo, Manuel A Espinoza, Pilar Contreras-Montiel, Carlos Balmaceda
Förderung
- Roche
Zitieren
APA
Armijo, N., Espinoza, M. A., Contreras-Montiel, P., Vera, M., & Balmaceda, C. (2026). Cost-effectiveness of primary HPV genotyping and dual-stain or cytology reflex testing versus cytology-based screening for cervical cancer in Chile. PLOS One, 21(3), e0332010. https://doi.org/10.1371/journal.pone.0332010
Vancouver
Armijo N, Espinoza MA, Contreras-Montiel P, Vera M, Balmaceda C. Cost-effectiveness of primary HPV genotyping and dual-stain or cytology reflex testing versus cytology-based screening for cervical cancer in Chile. PLOS One. 2026;21(3):e0332010. doi:10.1371/journal.pone.0332010
BibTeX
@article{Armijo2026,
author = {Armijo, Nicolas and Espinoza, Manuel A and Contreras-Montiel, Pilar and Vera, Macarena and Balmaceda, Carlos},
title = {Cost-effectiveness of primary HPV genotyping and dual-stain or cytology reflex testing versus cytology-based screening for cervical cancer in Chile},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {3},
pages = {e0332010},
doi = {10.1371/journal.pone.0332010}
}
EUVIMED